 SAN DIEGO, March 24, 2021 PRNewswire -- Evofem Biosciences, Inc. NASDAQ: EVFM today announced that it intends to offer and sell, subject to market and other conditions, 30 million of shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 4.5 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. 